Table 3.
Profile of prostanoid production in inner medulla of vehicle-treated rats and rats treated with a cyclooxygenase-1 inhibitor (SC-560) in BUO rats for 12 and 24 h and sham-operated control rats
| Time, h | PGE2 | 6-Keto-PGF1α | PGF2α | TxB2 | PGD2 |
|---|---|---|---|---|---|
| 12 | |||||
| Sham | 1.4 ± 0.4 | 1.2 ± 0.3 | 1.3 ± 0.2 | 0.20 ± 0.03 | 0.11 ± 0.01 |
| BUO | 10.1 ± 1.8* | 7.0 ± 4.2* | 4.3 ± 0.7* | 0.35 ± 0.01* | 0.30 ± 0.02* |
| BUO + SC-560 | 5.1 ± 1.0†‡ | 5.4 ± 0.7‡ | 2.7 ± 0.4†‡ | 0.29 ± 0.03 | 0.20 ± 0.02† |
| 24 | |||||
| Sham | 0.95 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 2.8 | 0.74 ± 0.12 | 0.25 ± 0.04 |
| BUO | 5.0 ± 1.2* | 4.4 ± 0.7* | 4.8 ± 1.3 | 0.55 ± 0.08 | 0.43 ± 0.16 |
| BUO + SC-560 | 4.5 ± 0.6‡ | 3.2 ± 0.4‡ | 4.8 ± 1.6 | 0.59 ± 0.09 | 0.21 ± 0.03 |
Values are means ± SE for n = 6 rats in each group. Units are pg/μg tissue. P < 0.05, respective prostanoids in nontreated BUO vs. sham-operated control rats (*), respective prostanoids in nontreated BUO vs. SC-560-treated BUO rats (†), and respective prostanoids in SC-560-treated BUO vs. sham-operated control rats (‡).